Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Payables (2017 - 2025)

Historic Payables for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $33.7 million.

  • Crinetics Pharmaceuticals' Payables rose 8428.28% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.7 million, marking a year-over-year increase of 8428.28%. This contributed to the annual value of $21.5 million for FY2024, which is 744.52% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Payables is $33.7 million, which was up 8428.28% from $38.1 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Payables peaked at $38.1 million during Q2 2025, and registered a low of $6.2 million during Q3 2021.
  • Its 5-year average for Payables is $19.2 million, with a median of $18.3 million in 2024.
  • In the last 5 years, Crinetics Pharmaceuticals' Payables crashed by 2510.85% in 2021 and then skyrocketed by 13977.61% in 2022.
  • Crinetics Pharmaceuticals' Payables (Quarter) stood at $8.5 million in 2021, then soared by 81.28% to $15.4 million in 2022, then skyrocketed by 51.1% to $23.2 million in 2023, then dropped by 7.45% to $21.5 million in 2024, then soared by 56.85% to $33.7 million in 2025.
  • Its Payables stands at $33.7 million for Q3 2025, versus $38.1 million for Q2 2025 and $31.6 million for Q1 2025.